Alle Fotos(1)

Wichtige Dokumente

Ursprungszeugnis (CoO)/Analysenzertifikate (CoA)

Gesamtdokumentation anzeigen

E-067

Ethosuximide solution

Name: Ethosuximide solution
Brand: CERILLIAN

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):

C₇H₁₁NO₂

CAS-Nummer:

77-67-8

Molekulargewicht:

141.17

EG-Nummer:

200-659-6

UNSPSC-Code:

41116107

Dieses Produkt wurde eingestellt. Setzen Sie sich mit dem technischen Dienst in Verbindung.zur Unterstützung

Qualität

certified reference material

Leistungsmerkmale

Snap-N-Spike^®/Snap-N-Shoot^®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant^®

Konzentration

1.0 mg/mL in methanol

Format

single component solution

Lagertemp.

−20°C

SMILES String

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChIKey

HAPOVYFOVVWLRS-UHFFFAOYSA-N

Angaben zum Gen

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

Allgemeine Beschreibung

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike^® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signalwort

Danger

H-Sätze

H225,H301 + H311 + H331,H370

P-Sätze

P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Zulassungslistungen

Zulassungslistungen werden hauptsächlich für chemische Produkte erstellt. Für nicht-chemische Produkte können hier nur begrenzte Angaben gemacht werden. Kein Eintrag bedeutet, dass keine der Komponenten gelistet ist. Es liegt in der Verantwortung des Benutzers, die sichere und legale Verwendung des Produkts zu gewährleisten.

EU REACH Annex XVII (Restriction List)

CAS No.

67-56-1

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy.

Gabi Dezsi et al.

Epilepsia, 54(4), 635-643 (2013-03-08)

Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures. Chronic treatment with ESX has been reported to have disease-modifying antiepileptogenic activity in the WAG/Rij rat model of genetic generalized epilepsy (GGE) with absence seizures. Here

Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.

Emilio Russo et al.

Epilepsia, 52(7), 1341-1350 (2011-06-04)

Depression is most commonly associated with epilepsy. Recent reports have suggested a putative relationship between seizure development and onset of depressive behavior, whereas others proposed that two clinical entities might represent different neuropathologic aspects of the same neurologic disorder. The

Ethosuximide and phenobarbital promote wound healing via enhancing collagenization.

Dema M Ajwee et al.

Chemical biology & drug design, 79(1), 137-142 (2011-02-22)

The fact that ethosuximide (ETO), phenobarbital (PHO), and barbituric acid (BARB) share structural and pharmacophoric homologies with phenytoin and allantoin, both known to have significant wound-healing properties, prompted us to evaluate them as wound-healing agents. Accordingly, ETO-, PHO-, and BARB-containing

Does antiepileptogenesis affect sleep in genetic epileptic rats?

Gilles van Luijtelaar et al.

International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 85(1), 49-54 (2011-09-29)

Recently it was established that early long lasting treatment with the anti-absence drug ethosuximide (ETX) delays the occurrence of absences and reduces depressive-like symptoms in a genetic model for absence epilepsy, rats of the WAG/Rij strain. Here it is investigated

Non-convulsive status epilepticus of frontal origin in mucopolysaccharidosis type II successfully treated with ethosuximide.

Paolo Bonanni et al.

Developmental medicine and child neurology, 54(10), 961-964 (2012-03-15)

At 7 years of age, a female with mucopolysaccharidosis type II (MPS II) showed a sudden deterioration in neurological function, a sleep disorder, and progressive behavioural impairment. Electroencephalography was performed 1 year and 8 months after the onset of the

Alle zugehörigen Dokumente anzeigen

Fragen

Bewertungen

Kein Beurteilungswert

Aktive Filter

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.